4//SEC Filing
Shulman Joseph 4
Accession 0001104659-25-100851
CIK 0001649904other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:30 PM ET
Size
17.2 KB
Accession
0001104659-25-100851
Insider Transaction Report
Form 4
Shulman Joseph
Chief Technical Officer
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2025-10-16−2,093→ 14,657 totalExercise: $27.35Exp: 2033-01-31→ Common Stock (2,093 underlying) - Exercise/Conversion
Common Stock
2025-10-16$30.66/sh+12,344$378,467→ 22,946 total - Sale
Common Stock
2025-10-16$110.95/sh−2,693$298,784→ 20,253 total - Exercise/Conversion
Common Stock
2025-10-16$27.35/sh+2,093$57,244→ 10,602 total - Sale
Common Stock
2025-10-16$112.06/sh−8,332$933,646→ 11,921 total - Sale
Common Stock
2025-10-16$112.81/sh−3,412$384,908→ 8,509 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-10-16−12,344→ 10,469 totalExercise: $30.66Exp: 2031-02-10→ Common Stock (12,344 underlying)
Footnotes (6)
- [F1]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $110.23 to $111.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.50 to $112.48 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.51 to $113.14 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F6]The stock option is fully vested.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001909855
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 4:30 PM ET
- Size
- 17.2 KB